<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042741</url>
  </required_header>
  <id_info>
    <org_study_id>V6</org_study_id>
    <nct_id>NCT03042741</nct_id>
  </id_info>
  <brief_title>Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity</brief_title>
  <acronym>V6</acronym>
  <official_title>Phase II Trial of Daily Dose of Oral Vaccine Against Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunitor LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunitor LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerosis vaccine, V6, has been through two small-scale Phase II open label clinical
      trials. It has shown significant improvement in lipid profile in patients with overweight or
      obesity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will evaluate daily dose of one V6 pill administered for one month in
      placebo-controlled, randomized, double-blind phase 3 trial in men and women with baseline
      waist diameter over 90 and 80 cm respectively. The effect of V6 will be assessed by changes
      in lipid profile, i.e., LDL, HDL, TG and TC; anthropomorphic indices, i.e., circumference of
      waist, mid-arm, and hips; arterial blood pressure and fasting glucose levels at baseline
      versus post-treatment timepoint.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">May 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group on experimental drug compared against group receiving placebo in randomized, blinded phase III study to evaluate effect on lipid profile, i.e., LDL, HDL, triglycerides and total cholesterol</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind study in two groups of patients assigned randomly into experimental and placebo arms</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Immunotherapy of atherosclerosis</measure>
    <time_frame>1 month</time_frame>
    <description>Effect on lipid profile as measured by changes in LDL, HDL, triglycerides and total cholesterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on anthropomorphic indices of obesity</measure>
    <time_frame>1 month</time_frame>
    <description>Effect on diameter of waist, mid-arm and hip after one month of treatment versus baseline measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on hypertension</measure>
    <time_frame>1 month</time_frame>
    <description>The systolic and diastolic blood pressures measured one month apart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on glucose levels</measure>
    <time_frame>1 month</time_frame>
    <description>Changes in fasting glucose levels from baseline to post-treatment time-point</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>V6 recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo recipients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>atherosclerosis vaccine</intervention_name>
    <description>Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue</description>
    <arm_group_label>V6 recipients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo pills</intervention_name>
    <description>Half of the patients will be randomly assigned to receive placebo pill</description>
    <arm_group_label>Placebo recipients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Baseline waist diameter over 90 and 80 cm for men and women, respectively

        Exclusion Criteria:

          -  Pregnant and lactating women

          -  Individuals with clinical symptoms or diseases who in opinion of study investigators
             are not eligible to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Bain, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Immunitor Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>aldar bourinbayar, PhD, MD/PhD</last_name>
    <phone>3014760930</phone>
    <email>IMMUNITOR@GMAIL.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>galyna kutsyna, MD, MD/PhD</last_name>
    <phone>0380508923222</phone>
    <email>kutsynagalyna@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Immunitor LLC</name>
      <address>
        <city>Ulaanbaatar</city>
        <state>CA</state>
        <zip>13838</zip>
        <country>Mongolia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aldar bourinbaiar</last_name>
      <phone>3014760930</phone>
      <email>aldar@immunitor.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mongolia</country>
  </location_countries>
  <reference>
    <citation>Bourinbaiar AS, Jirathitikal V. Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices. Vaccine. 2010 Mar 24;28(15):2763-8. doi: 10.1016/j.vaccine.2010.01.032. Epub 2010 Jan 29.</citation>
    <PMID>20117273</PMID>
  </reference>
  <reference>
    <citation>Bourinbaiar AS, Jirathitikal V. Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study. Lipids Health Dis. 2010 Feb 2;9:14. doi: 10.1186/1476-511X-9-14.</citation>
    <PMID>20122177</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be shared without identification of participants</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

